Trial Profile
Ruxolitinib prior to allogenic stem cell transplant in patients with myelofibrosis
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Aug 2014
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 14 Aug 2014 New trial record
- 07 Dec 2013 Primary endpoint has been met. (Improvement in symptoms)